Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 18;13(12):100864. doi: 10.1016/j.tranon.2020.100864

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 4 — Case of TIPS combined with subsequent antitumor treatment.

A 59-year-old male patient, primary hepatocellular carcinoma(HCC) with a diameter of 5 cm. He had experienced a splenic arterial embolization due to hypersplenism. Because of his refractory ascites, the patient only received a transarterial chemoembolization (TACE) within 6 months after diagnosed with HCC. a-b. ascites and tumor before transjugular intrahepatic portosystemic shunt(TIPS). The Child-Pugh score and Child-Pugh stag were 8 and B; c. TIPS was completed. d. One month after TIPS, the ascites completely disappeared. The re-evaluated Child-Pugh score and Child-Pugh stag were 6 and A. e-f. Patients received subsequent microwave ablation because of the improved liver function. Subsequently, the patient experienced multiple ablation and TACE because of his intrahepatic recurrent tumors, and finally died of tumor progression. The overall survival was 18.5 months (from TIPS) but the ascites did not reappear.